{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060455","form_type":"8-K","ticker":"KOD","cik":"0001468748","company_name":"Kodiak Sciences Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.552307+00:00","generated_at":"2026-06-01T22:55:22.590887+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Kodiak Sciences Q1 net loss $43M, cash $245.9M; advances tarcocimab and KSI-101 trials","bullets":["Net loss of $43.0M ($0.82 per share) vs $70.8M ($1.35) in Q1 2023; includes $18.4M stock-based compensation.","Cash and equivalents $245.9M; company expects runway into 2026.","R&D expenses $29.9M, down from $56.5M YoY due to reduced tarcocimab clinical activities.","GLOW2 Phase 3 diabetic retinopathy study actively enrolling; DAYBREAK wet AMD study activation targeted mid-2024.","Phase 1b APEX study of KSI-101 (anti-IL-6/VEGF-trap) in macular edema expected to start enrollment in June 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060455","json":"https://secwatch.observer/filing/0000950170-24-060455.json","markdown":"https://secwatch.observer/filing/0000950170-24-060455.md","text":"https://secwatch.observer/filing/0000950170-24-060455.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1468748/000095017024060455/0000950170-24-060455-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1468748/000095017024060455/kod-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:55:22.590887+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b108ec1c9d7691a7d47fad3064e5792ad565df4b","claim":"Kodiak Sciences Inc. reported the quarter ended March 31, 2024 results: net income $43.0 million, or $0.82 per share on both a basic and diluted basis, EPS $0.82 per share on both a basic and diluted basis.","evidence_excerpt":"Kodiak Sciences Inc. (Nasdaq: KOD), today reported business highlights and financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1468748/000095017024060455/0000950170-24-060455-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$43.0 million, or $0.82 per share on both a basic and diluted basis"},{"label":"EPS","value":"$0.82 per share on both a basic and diluted basis"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}